Cargando…
First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
BACKGROUND: With poor prognosis and limited treatment options for advanced hepatocellular carcinoma (HCC), development of novel therapeutic agents is urgently needed. This single-arm phase I study sought to assess the safety and preliminary efficacy of icaritin in human as a potential oral immunothe...
Autores principales: | Fan, Ying, Li, Shu, Ding, Xiaoyan, Yue, Jian, Jiang, Jun, Zhao, Hong, Hao, Rui, Qiu, Weiliang, Liu, Kezhen, Li, Ying, Wang, Shengdian, Zheng, Limin, Ye, Bin, Meng, Kun, Xu, Binghe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437929/ https://www.ncbi.nlm.nih.gov/pubmed/30922248 http://dx.doi.org/10.1186/s12885-019-5471-1 |
Ejemplares similares
-
Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation
por: Tao, Huimin, et al.
Publicado: (2021) -
Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
por: Qin, Shu‐Kui, et al.
Publicado: (2020) -
Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
por: Lu, Yi, et al.
Publicado: (2022) -
A comparative study on the in vitro and in vivo antitumor efficacy of icaritin and hydrous icaritin nanorods
por: Li, Haowen, et al.
Publicado: (2020) -
Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
por: Lu, Yi, et al.
Publicado: (2023)